Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Scott Rottinghaus, MD
Advertisement
Rottinghaus is chief medical officer of Enanta Pharmaceuticals.
Articles by Scott Rottinghaus, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
4
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
5